OSR (NASDAQ:OSRH) Releases Quarterly Earnings Results

OSR (NASDAQ:OSRH) announced its quarterly earnings results on Wednesday. The company reported ($0.09) earnings per share (EPS) for the quarter, Zacks reports. OSR had a negative return on equity of 7.16% and a negative net margin of 363.26%.The firm had revenue of $0.48 million during the quarter.

OSR Stock Performance

Shares of OSRH stock traded down $0.03 during mid-day trading on Friday, hitting $0.57. The company’s stock had a trading volume of 1,092,192 shares, compared to its average volume of 4,981,995. The stock has a market cap of $19.97 million, a price-to-earnings ratio of -1.72 and a beta of 0.86. OSR has a 52-week low of $0.38 and a 52-week high of $1.79. The business has a 50-day moving average price of $0.54 and a 200 day moving average price of $0.58.

Institutional Investors Weigh In On OSR

A hedge fund recently bought a new stake in OSR stock. Susquehanna International Group LLP bought a new position in OSR Holdings, Inc. (NASDAQ:OSRH) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned about 0.37% of OSR as of its most recent filing with the SEC. Institutional investors and hedge funds own 55.30% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on OSRH. Wall Street Zen upgraded shares of OSR from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of OSR in a report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.